People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Arcellx, Inc. | — | Biotechnology | Series D+ | $272.8M | $1.8B | 2021 |
| Dyne Therapeutics, Inc. | — | Biotechnology | Series D+ | $115.7M | $4.6B | 2020 |
| Tetraphase Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $64.7M | $350.8M | 2009 |
David Lubner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Lubner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ali Behbahani | 1 | 17 |
| Robert Weisskoff | 1 | 12 |
| Tiba Aynechi | 1 | 9 |
| Lawrence Miller | 1 | 8 |
| John G. Freund | 1 | 6 |
| Lewis T. Williams | 1 | 5 |
| Douglas Cole | 1 | 5 |
| Jill Carroll | 1 | 4 |
| Derek Yoon | 1 | 4 |
| Jason Rhodes | 1 | 3 |
| L. Patrick Gage | 1 | 3 |
| Karl D. Handelsman | 1 | 2 |
| Joshua Brumm | 1 | 2 |
| Richard Scalzo | 1 | 2 |
| Lance Thibault | 1 | 2 |
| Roger Sawhney | 1 | 2 |
| Kavita Patel | 1 | 2 |
| Edward Hurwitz | 1 | 2 |
| Hugo Beekman | 1 | 2 |
| Rami Elghandour | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.